About Aardvark Therapeutics, Inc. Common Stock
https://aardvarktherapeutics.comAardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
CEO
Tien-Li Lee
Compensation Summary
(Year )
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:408.67K
IWM
Weight:0.01%
Shares:290.93K
XSU.TO
Weight:0.01%
Shares:290.93K
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
DECHENG CAPITAL LLC
Shares:3.92M
Value:$58.68M
CITADEL ADVISORS LLC
Shares:1.36M
Value:$20.37M
LAURION CAPITAL MANAGEMENT LP
Shares:1.05M
Value:$15.72M
Summary
Showing Top 3 of 50
About Aardvark Therapeutics, Inc. Common Stock
https://aardvarktherapeutics.comAardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $17.69M ▲ | $-16.32M ▼ | 0% | $-0.75 ▼ | $-16.31M ▼ |
| Q2-2025 | $0 | $15.85M ▲ | $-14.37M ▼ | 0% | $-0.66 ▲ | $-15.84M ▼ |
| Q1-2025 | $0 | $10.47M ▲ | $-9.31M ▼ | 0% | $-0.71 ▼ | $-10.46M ▼ |
| Q4-2024 | $0 | $9.45M ▲ | $-8.78M ▼ | 0% | $-0.68 ▼ | $-9.44M ▼ |
| Q3-2024 | $0 | $5.09M | $-4.18M | 0% | $-0.32 | $-5.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $126.35M ▼ | $133.23M ▼ | $10.85M ▲ | $122.38M ▼ |
| Q2-2025 | $141.82M ▼ | $147.47M ▼ | $10.55M ▲ | $136.93M ▼ |
| Q1-2025 | $151.26M ▲ | $157.03M ▲ | $6.34M ▼ | $150.69M ▲ |
| Q4-2024 | $73.66M ▼ | $77.51M ▼ | $132.15M ▲ | $-54.64M ▼ |
| Q3-2024 | $82.36M | $83.74M | $129.91M | $-46.17M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.32M ▼ | $-18.52M ▼ | $29.25M ▲ | $2.56M ▲ | $13.29M ▲ | $-18.52M ▼ |
| Q2-2025 | $-14.37M ▼ | $-9.84M ▲ | $9.41M ▲ | $-71K ▼ | $-506K ▲ | $-9.94M ▲ |
| Q1-2025 | $-9.31M ▼ | $-11.39M ▼ | $-112.62M ▼ | $88.88M ▲ | $-35.14M ▼ | $-11.39M ▼ |
| Q4-2024 | $-8.78M ▼ | $-7.73M ▼ | $-11.89M ▼ | $-1.01M ▼ | $-20.64M ▼ | $-7.73M ▼ |
| Q3-2024 | $-4.18M | $-3.96M | $-5K | $64K | $-3.9M | $-3.96M |
CEO
Tien-Li Lee
Compensation Summary
(Year )
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:408.67K
IWM
Weight:0.01%
Shares:290.93K
XSU.TO
Weight:0.01%
Shares:290.93K
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
DECHENG CAPITAL LLC
Shares:3.92M
Value:$58.68M
CITADEL ADVISORS LLC
Shares:1.36M
Value:$20.37M
LAURION CAPITAL MANAGEMENT LP
Shares:1.05M
Value:$15.72M
Summary
Showing Top 3 of 50